Search research articles
Contact Us
Filters
Showing results (491-500 of 549) with videos related to
Page
of 55
Sort By:
The World Allergy Organization Journal
|
September 2, 2021
"Chronic urticaria and obstructive sleep apnea: Is there a significant association?"
Ivan Cherrez-Ojeda, Marcus Maurer, Miguel Felix, et al.
JCO Precision Oncology
|
April 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis
Sherene Loi, Roberto Salgado, Peter Schmid, et al.
The Lancet. Oncology
|
May 21, 2021
Chemotherapy de-escalation using an <sup>18</sup>F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
José Manuel Pérez-García, Geraldine Gebhart, Manuel Ruiz Borrego, et al.
The Lancet. Oncology
|
May 9, 2016
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
Ian E Krop, Ingrid A Mayer, Vinod Ganju, et al.
Microbiome Research Reports
|
April 10, 2025
Profiling the gut and oral microbiota of hormone receptor-positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin
Nancy My Teng, Andrea Malfettone, Matthew J Dalby, et al.
Frontiers in Allergy
|
September 26, 2022
Corrigendum on: White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by EUFOREA
Louise De Prins, Ulrike Raap, Tara Mueller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2024
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer
Komal L Jhaveri, Melissa K Accordino, Philippe L Bedard, et al.
Allergy
|
March 22, 2023
Atopic dermatitis: Correlation of distinct risk factors with age of onset in adulthood compared to childhood
Laura Maintz, Marie-Therese Schmitz, Nadine Herrmann, et al.
The World Allergy Organization Journal
|
April 1, 2014
Sublingual immunotherapy: World Allergy Organization position paper 2013 update
Giorgio Walter Canonica, Linda Cox, Ruby Pawankar, et al.
The Oncologist
|
October 14, 2022
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, et al.
Page
of 55
Search research articles
Search
Showing results (491-500 of 549) with videos related to
Sort By:
Page
of 55
The World Allergy Organization Journal
|
September 2, 2021
"Chronic urticaria and obstructive sleep apnea: Is there a significant association?"
Ivan Cherrez-Ojeda, Marcus Maurer, Miguel Felix, et al.
JCO Precision Oncology
|
April 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis
Sherene Loi, Roberto Salgado, Peter Schmid, et al.
The Lancet. Oncology
|
May 21, 2021
Chemotherapy de-escalation using an <sup>18</sup>F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
José Manuel Pérez-García, Geraldine Gebhart, Manuel Ruiz Borrego, et al.
The Lancet. Oncology
|
May 9, 2016
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
Ian E Krop, Ingrid A Mayer, Vinod Ganju, et al.
Microbiome Research Reports
|
April 10, 2025
Profiling the gut and oral microbiota of hormone receptor-positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin
Nancy My Teng, Andrea Malfettone, Matthew J Dalby, et al.
Frontiers in Allergy
|
September 26, 2022
Corrigendum on: White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by EUFOREA
Louise De Prins, Ulrike Raap, Tara Mueller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2024
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer
Komal L Jhaveri, Melissa K Accordino, Philippe L Bedard, et al.
Allergy
|
March 22, 2023
Atopic dermatitis: Correlation of distinct risk factors with age of onset in adulthood compared to childhood
Laura Maintz, Marie-Therese Schmitz, Nadine Herrmann, et al.
The World Allergy Organization Journal
|
April 1, 2014
Sublingual immunotherapy: World Allergy Organization position paper 2013 update
Giorgio Walter Canonica, Linda Cox, Ruby Pawankar, et al.
The Oncologist
|
October 14, 2022
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, et al.
Page
of 55